Drug Trial Radar · NCT06922318
The COSMYC Trial (COmbined Suppression of MYC)
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 19, 2025
Primary completion
Aug 30, 2031
Study completion Aug 30, 2031
Sponsor
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Zenith Epigenetics; National Cancer Institute (NCI)
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
ZEN-3694Drug
ZEN-3694 is available in two capsule strengths for this study: 12 mg and 48 mg.
Testosterone cypionateDrug
On day 1 of each BATZEN cycle testosterone cypionate (400 mg) injection to the buttocks will be administered.
EnzalutamideDrug
Enzalutamide 160 mg (four 40 mg tablets) taken daily by mouth on each ZENZA cycle.
Luteinizing hormone-releasing hormone (LHRH) analogueDrug
Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout the duration of the study to inhibit endogenous testosterone production.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical/radiographic progression free survival (PFS) with BATZENTime frame: 2 years
- Prostate specific antigen (PSA)-Progression free survival (PFS) with ZENZATime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.